Abstract
AbstractReducing or eliminating persistent disparities in lung cancer incidence and survival has been challenging because our current understanding of lung cancer biology is derived primarily from populations of European descent. Here we show results from a targeted sequencing panel using NCI-MD Case Control Study patient samples and reveal a significantly higher prevalence of PTPRT and JAK2 mutations in lung adenocarcinomas among African Americans compared with European Americans. This increase in mutation frequency was validated with independent WES data from the NCI-MD Case Control Study and TCGA. We find that patients carrying these mutations have a concomitant increase in IL-6/STAT3 signaling and miR-21 expression. Together, these findings suggest the identification of these potentially actionable mutations could have clinical significance for targeted therapy and the enrollment of minority populations in clinical trials.
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry
Reference49 articles.
1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 69, 7–34 (2019).
2. Schneiderman, M. A. & Levin, D. L. Trends in lung cancer. Mortality, incidence, diagnosis, treatment, smoking, and urbanization. Cancer 30, 1320–1325 (1972).
3. Burbank, F. & Fraumeni, J. F. U. S. cancer mortality: nonwhite predominance. J. Natl Cancer Inst. 49, 649–659 (1972).
4. Ryan, B. M. Lung cancer health disparities. Carcinogenesis 39, 741–751 (2018).
5. Holford, T. R., Levy, D. T. & Meza, R. Comparison of smoking history patterns among African American and white cohorts in the United States born 1890 to 1990. Nicotine Tob. Res. 18(Suppl 1), S16–S29 (2016).
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献